Reading the presentation, I was reminded of the Arrowhead Research concerning homing peptides:
http://www.arrowheadresearch.com/technology/homing-peptides
Delivery of canonical (and especially certain classes of non-canonical) siRNA is a very big business.
This could be an "market disruptive" development that PYC could exploit.
Silencing siRNA (over a protein class) could lead the way for targetted therapeutics for Phylomers (silencing over a protein "phase").
Hence there is potential for PYC to participate in markets around siRNA delivery - which is currently a very lucrative place to be.
Reading the presentation, I was reminded of the Arrowhead...
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
0.010(5.26%) |
Mkt cap ! $933.2M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 20.0¢ | 18.8¢ | $963.9K | 4.978M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2692 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 445208 | 3 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| PYC (ASX) Chart |